Outlook Therapeutics (OTLK) Research & Development (2015 - 2026)

Outlook Therapeutics (OTLK) has reported Research & Development for 12 consecutive years, with $3.3 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Research & Development fell 54.43% year-over-year to $3.3 million in Q2 2026; TTM through Jun 2026 was $17.4 million, a 48.51% decrease from a year earlier, with the FY2025 full-year figure at $27.2 million, down 34.92% from the prior year.
• Research & Development was $3.3 million for Q2 2026 at Outlook Therapeutics, down from $4.5 million in the prior quarter.
• Over five years, Research & Development peaked at $13.5 million in Q1 2024 and troughed at $544948.0 in Q1 2023.
• A 5-year average of $7.7 million and a median of $8.1 million in 2022 frame the typical range for Research & Development.
• Across the five-year window, Research & Development sank 95.54% in 2023 and soared 2378.94% in 2024, its largest moves.
• Over 5 years, Research & Development stood at $9.9 million in 2022, then sank by 54.07% to $4.5 million in 2023, then jumped by 113.28% to $9.7 million in 2024, then tumbled by 62.38% to $3.6 million in 2025, then fell by 10.55% to $3.3 million in 2026.
• The last three Research & Development figures came in at $3.3 million (Q2 2026), $4.5 million (Q1 2026), and $3.6 million (Q4 2025), per Business Quant data.